^○Hideki Kasuya^1,2 (1.Nagoya University Graduate School of Medicine、Cancer Immune Therapy Center, 2.CEO, Onco Immune Therathech Co. LTD)

^○Ken-ichiro Kosai^1,2, 永野 聡^1,2,3 (1.Kagoshima University Graduate School of Medical and Dental Sciences / Kagoshima University Hospital, 2.鹿児島大学病院, 3.鹿児島大学医学部保健学科)

^○Kazunori Aoki¹, Nobuyoshi Hiraoka¹, 光永 修一² (1.National Cancer Center Research Institute, 2.国立がん研究センター東病院)

^○Masato Yamamoto (University of Minnesota)